Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 112 |
| Active Pipeline (Recruiting Now) | 59 (43) |
| Completed vs Stopped Early | 34 / 19 (17.0%) |
| Median Closed Actual Enrollment | 48 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05931276 | CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | Phase III | RECRUITING |
| NCT05011383 | High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers | Phase II | RECRUITING |
| NCT05593497 | A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inh | Phase II | RECRUITING |
| NCT05212246 | Basal Cell Carcinoma Chemoprevention Trial | Phase III | RECRUITING |
| NCT04038502 | Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the VA Office of Research and Development Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.